$SPRCJul 27, 2026, 12:25 PMAI processed
SciSparc to Target Agentic AI Market, Forms AI & Cybersecurity Scientific Advisory Board
AI Summary
SciSparc (SPRC) said its board has decided to target the agentic AI market and has formed a Scientific Advisory Board focused on artificial intelligence and cybersecurity while evaluating opportunities and holding discussions with several agentic-AI companies. The firm remains a clinical-stage cannabinoid/pharma developer via majority-owned NeuroThera and cautioned the AI initiative is exploratory with no committed deals, timelines, or financial details.
Positives
- Board formally decided to target the agentic AI market and established a Scientific Advisory Board for AI and cybersecurity
- Company is evaluating opportunities and is in discussions with multiple agentic-AI companies
- Move could diversify SciSparc’s strategic focus beyond its existing cannabinoid drug programs
Negatives
- No acquisitions, partnerships, financing, timelines, or deal terms were announced
- Company warned in the release that it may not ultimately identify or realize opportunities in the agentic AI field
- No details provided on funding, resource allocation, or execution plan for the AI initiative